Latest Revenue Streaming News

SGH Ltd reported a solid half-year profit of $472.6 million, declaring a fully franked 32 cent dividend, while completing a major media merger that reshapes its investment portfolio.

Computershare Limited reported a 5.4% increase in revenue to $1.58 billion for the half-year ended December 2025, driven by growth across its core businesses. However, profit after tax slipped 2.6%, weighed down by disposal costs and rising expenses related to the UK Mortgage Services sale.

The Agency Group Australia reports robust Q2 FY26 growth with a 41% jump in Gross Commission Income and expanding national footprint. The company is accelerating its push into East Coast markets while managing supply constraints in Western Australia.

Tartana Minerals secures $4.5 million to ramp up exploration at its Nightflower Silver-Lead-Zinc-Antimony project and appoints a new director to bolster governance.

Aura Energy has successfully raised A$20 million through a share placement, while ongoing confidential negotiations aim to secure critical offtake agreements for its uranium and polymetallic projects.

Kincora Copper has reported promising initial results from its Phase 1 drilling at Nevertire, prompting an expansion of exploration activities and recommencement of drilling to target multiple porphyry centres.

PLS Group has locked in a two-year offtake agreement with Canmax Technologies for 150,000 tonnes per annum of spodumene concentrate, backed by a $100 million interest-free prepayment and a price floor to protect against market dips.

StepChange Holdings has reported robust organic growth with a 19% revenue increase in its first half as an ASX-listed company, complemented by a strategic acquisition expanding its government sector presence.

TG Metals has lodged a provisional patent application for a new technology that significantly improves lithium recovery and concentrate quality at its Burmeister deposit in Western Australia.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.